Open AccessThe Role of Public–Private Partnerships in Catalyzing the Critical Path
Author(s) -
Maxfield Kimberly E.,
BuckmanGarner ShaAvhrée,
Parekh Ameeta
Publication year - 2017
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12488
Subject(s) - path (computing) , medline , medicine , business , public relations , political science , computer science , law , computer network
The US Food and Drug Administration (FDA)’s Critical Path Initiative (CPI) was launched in 2004 and aimed at accelerating the stagnating product development pipeline. Subsequently, in 2006, the Critical Path Opportunities List (CPOL) identified specific priorities to facilitate the CPI vision. Since then, the FDA’s Center for Drug Evaluation and Research directed considerable efforts to achieve the goals of CPI and CPOL. Collaborations with Public–Private Partnerships (PPPs) helped address several CPOL priorities to yield meaningful results to benefit public health.